Sununu John E
Known title: DirectorCIK: 0001458974
Associated companies
Transaction History
| BSX | ▲ Buy | Grant | 2,081 | $0 | 5/8/2025 | View on chart |
| BSX | ▲ Buy | Grant | 2,901 | $0 | 5/9/2024 | View on chart |
| BSX | ▲ Buy | Grant | 3,946 | $0 | 5/4/2023 | View on chart |
| BSX | ▲ Buy | Grant | 4,877 | $0 | 5/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.